The Award-Winning AbinoNutra® NMN Bulk Powder
AbinoNutra® NMN bulk powder is a core ingredient in our healthy longevity ingredient portfolio. Produced in a US FDA-registered facility adhering to stringent cGMP standards, our NMN offers both chemical and optical purities exceeding 99.0%. It has been recognized as SA-GRAS by experts accredited by the US FDA and has been successfully marketed in the US and Japan since 2020. We have completed one of the most comprehensive and successful human clinical trials on AbinoNutra® NMN for healthy longevity, with an additional four trials currently underway in Taiwan, Japan, and Singapore. Notably, we collaborate closely with Professor Andrea Maier, director of the Center for Health Longevity at the National University of Singapore, on human clinical studies involving AbinoNutra® NMN to further conform its diverse applications for healthy aging. Our extensive research on AbinoNutra® NMN ingredient has garnered significant attention from both the academic and nutritional industries.
COA of AbinoNutra® NMN
A typical Certificate of Analysis (COA) for AbinoNutra®️ NMN with regular particle size is presented here, suitable for capsule and tablet dosage forms. Additionally, a finer powder with smaller particle size is available for powder dosage forms. A lyophilized powder for cosmetic applications can also be provided upon request.
AbinoNutra® NMN: Award and Media Coverage
AbinoNutra® NMN: Award and Media Coverage
NMN stands for β-nicotinamide mononucleotide which is a natural substance that exists in all cells of human tissues or organs and also lots of plants, such as broccoli, cabbage, avocado, etc.
NMN is a very important precursor of coenzyme I (NAD⁺). The cells in our body use NMN to make NAD⁺. NAD⁺ plays an essential role in our body for converting the food into energy and participating many other important biological functions, such as DNA repair and cell revitalization, that are directly related to our overall health.
Chemically, NMN belongs to vitamin B3 which is a group of natural chemical compounds called niacin. These niacins include NA (nicotinic acid), NAM (nicotinamide), NR (nicotinamide riboside), and their derivatives, such as NMN. Niacins are all NAD⁺ precursors that can be converted into NAD⁺ through various biological pathways in human cells as shown in the graph. Among all these NAD⁺ precursors, NMN is relatively more efficient to be converted to NAD⁺.
However, the level of NAD⁺ in human body decreased dramatically when people get older. The decrease of NAD⁺ with aging causes cell malfunctions and has direct impact on many age-related health issues, such as obesity, diabetes, cardiovascular issues, memory, eye function, etc. A lot of scientific researches during past few decades have confirmed that NMN intake can increase NAD⁺ levels and rejuvenate cell functions of aging animals. For more details of scientific researches on NMN and anti-aging, please see our blog on NMN and human longevity and www.nmn.com.
Besides taking NAD⁺ precursor supplements, such as NMN, scientific researches also confirmed that exercise, calorie restrict and healthy diet can help increase NAD⁺ levels to a certain degree in our body. Maintaining a healthy level of NAD⁺ is essential for the biological functions of various organs in our body as shown in this picture.
NAD⁺ itself has low bioavailability and generally is not an efficient way to booster NAD⁺ in human body by orally taking NAD⁺ supplements.
Human Clinical Trials of AbinoNutra® NMN
Human Clinical Trials of AbinoNutra® NMN
NMN has been shown to significantly increase NAD⁺ levels in mice and other animals, resulting in slowed aging, delayed onset of frailty, and prevention of age-related diseases, thereby extending both the healthspan and lifespan of the animals −−− Imai (2016); Sinclair (2023).
However, earlier human studies on NMN yielded inconsistent results, notably failing to increase blood NAD⁺ levels in one clinical trial. These outcomes, along with other findings, have raised questions regarding the anti-aging effects of NMN.
AbinoNutra® NMN human clinical trials
In collaboration with Professor Andrea Maier at the Healthy Longevity Center, National University of Singapore, we conducted one of the largest human clinical trials on AbinoNutra® NMN. The study employed a randomized, double-blinded, parallel and placebo-controlled design—the gold standard in clinical research—across two clinical centers to ensure the reliability and accuracy of the results. Key findings from the trial are summarized below:
Blood NAD⁺ levels increased significantly and dose-dependently in all the 300 mg, 600 mg, and 900 mg daily oral dose groups. The 600 mg dose group showed the highest increase, with a 4.7-fold elevation over baseline, as illustrated in the graph below.
Physical strength and overall health improved significantly, as demonstrated in the accompanying images.
Biological age decreased by 4.1 years in the 300 mg group, 6.7 years in the 600 mg group, and 4.6 years in the 900 mg group, as shown in the images below.
Our human clinical trial, published in GeroScience in 2023, garnered significant attention from both the public and academic communities (www.nmn.com; lifespan.io). In 2024, our study was awarded the 3rd prize by the American Aging Association (AGE). The trial results, together with other recent human clinical studies, conclusively demonstrate that oral NMN is highly bioavailable in humans and significantly elevates blood NAD⁺ levels, contributing to noteworthy healthy aging effects.
Please complete the following form to receive our AbinoNutra® NMN ingredient product brochure, newsletter, and other related information.